Clinical research has become significantly more complex over the past decade. Advances in science, rising regulatory expectations ...
Tempest Therapeutics, Inc. TPST announced that it is planning to explore strategic options to advance the clinical studies on its pipeline candidates aimed at increasing stockholder value. The ...
UTRECHT, The Netherlands and PHILADELPHIA, Feb. 25, 2025 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (LVTX) (NASDAQ: LVTX, “LAVA,” “the Company”), a clinical-stage immuno-oncology company focused on ...
-- Continuing to advance potentially differentiated HER3 ADC, EO-1022, which utilizes an MMAE payload and glycan site-specific conjugation -- -- Plan to present preclinical data for EO-1022 at AACR ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback